IDH2 and myelodysplastic syndrome: Efficacy and tolerability of enasidenib alone and combined with azacytidine were examined in another trial, involving patients with high-risk IDH2-mutated MDS: the best result, which was a 100% response, was achieved in hypomethylating-agent naive patients.